Literature DB >> 2473842

Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase.

M Del Val1, K Münch, M J Reddehase, U H Koszinowski.   

Abstract

The regulation of antigen processing and presentation to MHC class I-restricted cytolytic T lymphocytes was studied in cells infected with murine cytomegalovirus. Recognition by cytolytic T lymphocytes of the phosphoprotein pp89, the immunodominant viral antigen expressed in the immediate-early phase of infection, was selectively prevented during the subsequent expression of viral early genes. The surface expression of MHC class I glycoproteins and their capacity to present externally added pp89-derived antigenic peptides were not affected. Because recognition of several other antigens occurred during the early phase, a general failure in processing and presentation was excluded. Since neither rate of synthesis, amount, stability, nor nuclear transport of pp89 was modified, the failure in recognition indicates a selective interference with pp89 antigen processing and presentation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473842     DOI: 10.1016/0092-8674(89)90845-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  44 in total

1.  A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.

Authors:  U Reusch; W Muranyi; P Lucin; H G Burgert; H Hengel; U H Koszinowski
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

2.  Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus.

Authors:  H Hengel; U Reusch; G Geginat; R Holtappels; T Ruppert; E Hellebrand; U H Koszinowski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  MHC class I-subversive gene functions of cytomegalovirus and their regulation by interferons-an intricate balance.

Authors:  C Benz; H Hengel
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

5.  Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope.

Authors:  M Del Val; H J Schlicht; H Volkmer; M Messerle; M J Reddehase; U H Koszinowski
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.

Authors:  T Hanke; F L Graham; K L Rosenthal; D C Johnson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.

Authors:  R Holtappels; J Podlech; G Geginat; H P Steffens; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor.

Authors:  R Thäle; P Lucin; K Schneider; M Eggers; U H Koszinowski
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 9.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

10.  Double fluorescence analysis of human cytomegalovirus (HCMV) infected human fibroblast cultures by flow cytometry: increase of class I MHC expression on uninfected cells and decrease on infected cells.

Authors:  M Steinmassl; K Hamprecht
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.